CD14 and ovarian cancer: In the Monocyte panel, reduction in the risk of ovarian cancer was associated with HLA DR on CD14+ CD16- monocyte (OR=0.823, 95%CI:0.74-0.916, P=3.381E-04), HLA DR on CD14+ monocyte (OR=0.819, 95%CI:0.734-0.913, P=3.365E-04), and HLA DR on monocyte (OR=0.824, 95%CI:0.73-0.93, P=0.002).